These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38264230)

  • 21. Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors.
    Wu MZ; Teng TK; Tsang CT; Chan YH; Lee CH; Ren QW; Huang JY; Cheang IF; Tse YK; Li XL; Xu X; Tse HF; Lam CSP; Yiu KH
    Eur Heart J Cardiovasc Pharmacother; 2024 Jan; 10(1):45-52. PubMed ID: 37942588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renoprotective effect of chronic treatment with sodium-glucose cotransporter 2 inhibitors and its associated factors in Japanese patients with chronic heart failure and diabetes.
    Yokouchi G; Horio T; Matsumoto N; Fukuda K; Yoshimura R; Fujiwara R; Matsuoka Y; Sakamoto Y; Iwashima Y; Oshiro Y; Fujimoto K; Kasayuki N
    Int J Cardiol Heart Vasc; 2022 Dec; 43():101152. PubMed ID: 36457725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
    Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
    Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of SGLT2 inhibitors on the intestinal bacterial flora in Japanese patients with type 2 diabetes mellitus.
    Kusunoki M; Hisano F; Matsuda SI; Kusunoki A; Wakazono N; Tsutsumi K; Miyata T
    Drug Res (Stuttg); 2023 Sep; 73(7):412-416. PubMed ID: 37236230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correction to: IAPP/amylin and β‑cell failure: implication of the risk factors of type 2 diabetes.
    Kanatsuka A; Kou S; Makino H
    Diabetol Int; 2018 Oct; 9(4):266. PubMed ID: 30605171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correction: New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes in Japan Diabetes Society (English version).
    Shimada A; Kawasaki E; Abiru N; Awata T; Oikawa Y; Osawa H; Kajio H; Kozawa J; Takahashi K; Chujo D; Noso S; Fukui T; Miura J; Yasuda K; Yasuda H; Imagawa A; Ikegami H
    Diabetol Int; 2024 Jul; 15(3):638-639. PubMed ID: 39101174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes.
    Woo VC
    Can J Diabetes; 2020 Feb; 44(1):61-67. PubMed ID: 31839265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
    van Hulten V; Driessen JHM; Starup-Linde JK; Al-Mashhadi ZK; Viggers R; Klungel OH; Souverein PC; Vestergaard P; Stehouwer CDA; van den Bergh JP
    Diabetes Obes Metab; 2023 Nov; 25(11):3235-3247. PubMed ID: 37503747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erratum: Publisher Correction: articles initially published in wrong volume.
    Cell Death Discov; 2019; 5():116. PubMed ID: 31312525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correction: A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes.
    Bouchi R; Kondo T; Ohta Y; Goto A; Tanaka D; Satoh H; Yabe D; Nishimura R; Harada N; Kamiya H; Suzuki R; Yamauchi T
    Diabetol Int; 2023 Oct; 14(4):446. PubMed ID: 37781468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study.
    Ng NM; Ng YS; Chu TK; Lau P
    BMC Prim Care; 2022 Dec; 23(1):317. PubMed ID: 36476327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of baseline urinary glucose levels on the relationship between sodium-glucose cotransporter 2 inhibitors and serum uric acid in Japanese patients with type 2 diabetes mellitus.
    Tanaka Y; Ota R; Hirata A; Yokoyama S; Nakagawa C; Uno T; Hosomi K
    Pharmazie; 2023 Dec; 78(11):238-244. PubMed ID: 38178282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
    J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice?
    Fujiwara M; Shimizu M; Maejima Y; Shimomura K
    BMC Res Notes; 2022 Mar; 15(1):120. PubMed ID: 35351190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correction to: Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes.
    Komatsu H; Enomoto M; Shiraishi H; Morita Y; Hashimoto D; Nakayama S; Funakoshi S; Hirano S; Terada Y; Miyamura M; Fujimoto S
    Diabetol Int; 2020 Oct; 11(4):393. PubMed ID: 33090124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute Renal Failure, Ketoacidosis, and Urogenital Tract Infections with SGLT2 Inhibitors: Signal Detection Using a Japanese Spontaneous Reporting Database.
    Katsuhara Y; Ogawa T
    Clin Drug Investig; 2020 Jul; 40(7):645-652. PubMed ID: 32451843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
    Kobayashi K; Toyoda M; Kimura M; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Sato K; Miyakawa M
    Diab Vasc Dis Res; 2019 Jan; 16(1):103-107. PubMed ID: 30284913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
    Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
    Xu B; Li S; Kang B; Zhou J
    Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.